Russia fires economist who said it cannot win war of attrition
The state development bank confirmed Klepach's exit but gave no reason; The Bell reported chairman Igor Shuvalov acted after a call from above.
The 30-year yield touched a 19-year high on Tuesday, pushing borrowing costs higher for households.

Official series, each dated to the observation it comes from.
Federal Reserve Bank of St. Louis
The state development bank confirmed Klepach's exit but gave no reason; The Bell reported chairman Igor Shuvalov acted after a call from above.
Police in Greenville, South Carolina, found no signs of foul play, and her publicist said the death remains under investigation.
Prosecutors say Bridegan was lured from his car by a tire in the road and shot as his 2-year-old daughter sat strapped in the back seat.
Washington marked a year of the Guard deployment with a protest outside the White House, and the District's appeal over its legality is still pending.
Police data shows violent crime in Washington up 3 percent this year even as homicides fell 32 percent, on a table the department calls preliminary.
Watchdog groups asked ethics officials to investigate gala tickets Paramount gave FCC commissioners during its merger reviews. One wants the chairman disqualified.
In CDC data for 2024, 9,576 births were to mothers with foreign addresses. The Center for Immigration Studies puts it as high as 26,000.

Police are treating the death of the 41-year-old academic as unexpected but not suspicious; his family says he faced a sustained campaign of abuse.

Passed by Parliament last month, the law would have made France the first EU country to bar minors under 15 from social platforms.
The August 13 pre-pack transfers six stores, the online business and international franchises to Frasers, while the OXO Tower restaurant is sold separately.
The FDA approved the first influenza vaccine made with mRNA, months after refusing to review the application. Clearance for adults over 65 is conditional on a further study.
Grant overhead would be capped at 5 percent, down from 15, the engine of a claimed $2.2 billion saving the rule's own accounting puts at $0.94 billion.
AbbVie's Creon cost Medicare $1.49 billion in 2024 and the drug picked instead cost about half a billion less.